Lambert-Eaton Myasthenic Syndrome (LES)

The Shuman Law Firm Investigates Catalyst Pharmaceutical Partners, Inc. BOULDER, Colo., May 15, 2014 (BUSINESS WIRE) --  The Shuman Law Firm  announces that it is investigating potential claims against certain officers and directors of Catalyst Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”) (Nasdaq:  CPRX  ). Catalyst is as a Florida-based development-stage specialty pharmaceutical company. Catalyst’s major product is Firdapse which is used to treat Lambert-Eaton Myasthenic Syndrome (“LEMS”). The Firm’s investigation relates to allegations raised in a class action lawsuit against the Company relating to its disclosures regarding Firdapse and LEMS. The class action complaint alleges that the Company’s senior officers and/or directors mislead investors by (i) concealing that a competitor has been providing patients for free with a drug that is nearly biologically equivalent to the drug for which Catalyst seeks  Food and Drug Administration  (“FDA”) approval; (ii) overst